Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

2.7K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
2.7K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

5.0K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes.

Bone marrow transplantation·2016
Same author

Shaping the Molecular Landscape of Posttransplantation Lymphoproliferative Disorders.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same author

Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation.

Bone marrow transplantation·2015
Same author

The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2015
Same author

Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome.

Bone marrow transplantation·2015

Related Experiment Video

Updated: Apr 16, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

15.1K

Reduced-intensity conditioned allogeneic SCT in adults with AML.

R Reshef1, D L Porter1

  • 1Blood and Marrow Transplantation Program, Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Bone Marrow Transplantation
|March 3, 2015
PubMed
Summary

Reduced-intensity conditioned allogeneic stem cell transplant (RIC allo-SCT) is crucial for AML patients ineligible for myeloablative conditioning. Ongoing research explores alternative donors and personalized approaches to optimize RIC allo-SCT efficacy and safety.

More Related Videos

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

2.1K
Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
06:28

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

4.8K

Related Experiment Videos

Last Updated: Apr 16, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

15.1K
Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

2.1K
Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
06:28

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

4.8K

Area of Science:

  • Hematology
  • Oncology
  • Transplantation

Background:

  • Reduced-intensity conditioned allogeneic stem cell transplant (RIC allo-SCT) is a primary treatment for acute myeloid leukemia (AML), especially in older patients or those with comorbidities.
  • These regimens facilitate a graft-versus-leukemia (GVL) response while minimizing treatment toxicity compared to myeloablative conditioning.

Purpose of the Study:

  • To review the current status and evolving landscape of RIC allo-SCT in AML.
  • To discuss contemporary efficacy and toxicity data from recent studies.
  • To explore future directions including alternative donors and personalized treatment strategies.

Main Methods:

  • Review of recent retrospective and prospective cohort studies on RIC allo-SCT for AML.
  • Analysis of data on efficacy, toxicity, and patient eligibility.
  • Examination of emerging research on alternative donors and predictive factors.

Main Results:

  • RIC allo-SCT remains a standard of care for many AML patients unable to undergo myeloablative conditioning.
  • Mature efficacy and toxicity data from recent studies are now available for these attenuated regimens.
  • Research is advancing to incorporate alternative donors and personalized approaches to improve outcomes.

Conclusions:

  • RIC allo-SCT is essential for AML treatment, particularly for patients with comorbidities or advanced age.
  • The field is rapidly evolving with new strategies aimed at reducing toxicity and improving patient selection.
  • Future research focusing on alternative donors and predictive factors will further refine personalized RIC allo-SCT approaches in AML.